Bei Jing Shang Bao·2026-01-07 02:24Group 1 - The core point of the article is the significant management shake-up at Kunming Pharmaceutical Group, with the resignation of key executives and the appointment of new leadership from China Resources Sanjiu, indicating a deeper integration and control by the parent company amid performance pressures [1][2][3] Group 2 - The resignations include Chairman Wu Wendo, President Yan Wei, and Vice President Li Lichun, with Yu Xiang and Zhong Jiang taking over as Chairman and President, respectively, marking a shift in management less than a year after the last major changes [2][3] - The new management team has strong ties to China Resources, with Yu Xiang having extensive experience in the OTC and health sectors, and Zhong Jiang having risen through the ranks within the company [2][3] Group 3 - Kunming Pharmaceutical's performance has deteriorated significantly, with revenue dropping by 18.08% to 4.751 billion yuan and net profit declining by 39.42% to 269 million yuan in the first three quarters of 2025, marking the lowest figures in six years [4][5] - The company attributes its struggles to transitional pains from channel reforms and external pressures, including delayed execution of national traditional Chinese medicine procurement [5] Group 4 - The management changes are part of a broader strategy by China Resources to shift focus from external acquisitions to internal integration and operational efficiency, as evidenced by the expansion of the board from 9 to 15 members, with new directors from core management [3][6] - Recent personnel changes across various subsidiaries of China Resources indicate a strategic pivot towards internal consolidation following years of aggressive expansion [6][7] Group 5 - The success of the new management will depend on their ability to leverage their experience in the OTC sector to reverse the current downward trend in performance and align Kunming Pharmaceutical with the broader strategic goals of China Resources [5][7]